Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134039 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL31345946 | 0.87 | CES2 (0.44) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL27709578 | 0.86 | NPC1 (0.51) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL43492 | 0.85 | PIN1 (0.49) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL30675620 | 0.85 | ALDH1A1 (0.62) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL927338 | 0.85 | ALDH1A1 (0.62) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL1146881 | 0.83 | FFAR4 (0.55) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| Hydrochloric Acid SCHEMBL10990786 | 0.83 | ALDH1A1 (0.61) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL3337842 | 0.83 | PARP10 (0.52) | SMN1; SMN2NPC1RAB9AHTTLMNA | |
| SCHEMBL2336567 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240300951-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | BEIGENE LTD. (KY) | 2024-08-15 | — | — | US | disclosed |
| CN-115088722-B | Application, method and composition of diphenyl ether compound containing triazole structure in preventing and controlling plant diseases | 海利尔药业集团股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117836296-A | Pyrazolopyridone compounds | 百济神州有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-114805224-B | Ligustrazine chalcone derivative and preparation method and application thereof | 山东大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| CN-109942523-B | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| WO-2023082898-A1 | DIVALENT PLATINUM COMPLEX HAVING HIGH COLOR PURITY | 广东阿格蕾雅光电材料有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2022228490-A1 | POLYCYCLIC DERIVATIVE MODULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| EP-1068184-A1 | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6110956-A | ANTIDEPRESSANTS TREATING DISORDERS OF THE SEROTONIN-AFFECTED NEUROLOGICAL SYSTEMS | AMERICAN HOME PRODUCTS CORP. (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999051576-A1 | N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
| US-4670445-A | VASODILATORS | ELI LILLY AND COMPANY (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0113236-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES-PYRAZINES, AND -TRIAZINES | ELI LILLY AND COMPANY (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4636502-A | Methods of producing a positive inotropic effect or vasodilation by administration of 2-phenyl imidazo pyrimidines and pyrazines | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4578387-A | VASODILATION; DERIVATIVES OF 2-PHENYL-5,6,7,8-TETRAHYDROIMADAZO/1,2-A/PYRAZINE | ELI LILLY AND COMPANY (US) | 1986-03-25 | — | — | US | disclosed |
| EP-0154494-A2 | Phenylimidazole inotropic agents | ELI LILLY AND COMPANY (US) | 1985-09-11 | — | — | EP | disclosed |
| US-4537889-A | PHENYL SUBSTITUTED IMIDAZO COMPOUNDS | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0113236-A1 | Substituted imidazopyrimidines-pyrazines, and -triazines | ELI LILLY AND COMPANY (US) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300951-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | SMN1; SMN2 2823/4885NPC1 2052/4885RAB9A 981/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | SMN1; SMN2 3349/4885NPC1 306/4885RAB9A 1682/4885 |
| US-20240270751-A1 | Pyrazolopyridinone Compounds | NFATC1, CD4, PBK | SMN1; SMN2 2823/4885NPC1 2052/4885RAB9A 981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.